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Abstract
Background: Tuberculosis is an infectious bacterial disease caused by Mycobacterium tuberculosis. It remains a major
health threat, killing over one million people every year worldwide. An early antibiotic therapy is the basis of the
treatment, and the emergence and spread of multidrug and extensively drug-resistant mutant strains raise significant
challenges. As these bacteria grow very slowly, drug resistance mutations are currently detected using molecular
biology techniques. Resistance mutations are identified by sequencing the resistance-linked genes followed by
a comparison with the literature data. The only online database is the TB Drug Resistance Mutation database
(TBDReaM database); however, it requires mutation detection before use, and its interrogation is complex due to
its loose syntax and grammar.
Description: The MUBII-TB-DB database is a simple, highly structured text-based database that contains a set of
Mycobacterium tuberculosis mutations (DNA and proteins) occurring at seven loci: rpoB, pncA, katG; mabA(fabG1)-inhA,
gyrA, gyrB, and rrs. Resistance mutation data were extracted after the systematic review of MEDLINE referenced
publications before March 2013. MUBII analyzes the query sequence obtained by PCR-sequencing using two parallel
strategies: i) a BLAST search against a set of previously reconstructed mutated sequences and ii) the alignment of the
query sequences (DNA and its protein translation) with the wild-type sequences. The post-treatment includes the
extraction of the aligned sequences together with their descriptors (position and nature of mutations). The whole
procedure is performed using the internet. The results are graphs (alignments) and text (description of the mutation,
therapeutic significance). The system is quick and easy to use, even for technicians without bioinformatics training.
Conclusion: MUBII-TB-DB is a structured database of the mutations occurring at seven loci of major therapeutic
value in tuberculosis management. Moreover, the system provides interpretation of the mutations in biological
and therapeutic terms and can evolve by the addition of newly described mutations. Its goal is to provide easy
and comprehensive access through a client–server model over the Web to an up-to-date database of mutations
that lead to the resistance of M. tuberculosis to antibiotics.
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Background
Tuberculosis (TB) is an infectious disease caused by
a slow-growing bacterium, Mycobacterium tuberculosis,
which has been linked to humans since the beginning of
the early human expansion from east Africa [1]. Tubercu-
losis was the main cause of deaths in Western Europe
between the seventeenth century and the end of the nine-
teenth century [2]. It remains a major health threat, killing
more than a million individuals every year worldwide. Al-
though the WHO claims that its goal to halt and reverse
the TB epidemic by 2015 has already been achieved and
that the TB mortality rate has decreased by 41% since
1990, the global burden of TB remains. In 2011, there
were an estimated 8.7 million new cases of TB, and 1.4
million people died from TB.
No fully effective vaccination is possible because the
Bacille de Calmette et Guérin (BCG)-vaccine protection
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against TB varies among populations [3] and provides
only limited protection during childhood [4]. The limita-
tion of the TB expansion is thus based on the improve-
ment and generalization of diagnostic methods [5] and
early antibiotic therapy. The WHO recommends the
following combined therapy employing first-line antibi-
otics: rifampicin (or rifabutin), isoniazid, pyrazinamide
and ethambutol for two months followed by rifampicin
and isoniazid for four months [6].
However, irregular and low-dose treatment has led to
the emergence and spread of multidrug-resistant (MDR)
and extensively drug-resistant (XDR) Mycobacterium tu-
berculosis complex (MTBC) strains that present signifi-
cant challenges in disease control [6-8]. The resistance
increases in high MDR-TB burden countries, where the
number of cases was estimated to be 60,000 worldwide
in 2011. In these countries, the proportion of resistant
strains varies from 5 to 19% of new TB cases and up to
50% for retreatment cases. This increase in resistance
has led to the promotion of laboratory antimicrobial
testing for all isolates [6]. In the case of antibiotic resist-
ance, the therapy is conducted using second-line drugs,
such as aminoglycosides or non-conventional antibiotics
(such as fluoroquinolones).
The traditional phenotypic drug susceptibility test in-
duces serious delays in the detection of resistance due to
the extremely slow growth of M. tuberculosis, the answer
being obtained in most cases two weeks after the isola-
tion of the bacteria. Another drawback of the in vitro
susceptibility testing is the inadequate detection of re-
sistance to new drugs and to pyrazinamide [9-11]. The
rapid diagnosis of drug resistance by molecular methods
is essential to initiate effective antibiotic therapies and to
prevent the transmission of drug-resistant strains [12].
M. tuberculosis acquires drug resistance primarily
through mutations in specific genes [13,14]. The muta-
tions associated with drug resistance occur in rpoB for
rifampicin (RIF), in katG and the mabA (fabG1)-inhA op-
eron for isoniazid (INH), in pncA for pyrazinamide (PZA),
in rrs for amikacin (AMK) and in gyrA and gyrB for fluor-
oquinolones (FQs) [13,15-17].
Several commercial molecular kits are available to
detect M. tuberculosis resistance using line-probe as-
says or real-time PCR, and these kits allow for the pre-
diction of drug resistance in clinical specimens within
one working day [9]. They can detect the mutations
responsible for resistance to RIF alone (GeneXpert
MTB/RIF (Cepheid), INNO-LiPA® Rif. TB (Innogenetics)),
to RIF + INH (GenoType® MTBDRplus (Hain LifeScience
GmbH)), or to FQs +AMK (GenoType® MTBDRsl (Hain
LifeScience GmbH)), but their sensitivity varies, depend-
ing on the antibiotic [18]. These kits, unfortunately, detect
only the most frequent mutations [18,19]. An alternative
approach that allows for the exhaustive detection of
mutations consists of the PCR amplification and sequen-
cing of resistance-linked genes [20,21] and, more experi-
mentally, of complete genome sequencing [22]. It is,
however, time consuming to compare the sequences with
the reference genome and the mutation identity with the
literature data. Recently, Sandgren et al. [23] established a
comprehensive database that gathers information on the
mutations associated with TB drug resistance and the fre-
quency of the most common mutations associated with
resistance to specific drugs. The TBDReaM database is a
free online resource that allows for the molecular diagno-
sis of resistant TB after the processing of the amplified
sequences by any method. Although very helpful, the
TBDReaM database has not been updated since April
2010, and its usage remains time consuming because it
demands prior processing of the TB nucleotide sequences
to detect mutations and cannot be easily interrogated due
to its relaxed grammatical conception.
Here, we describe MUBII-TB-DB, a database of the
mutations of M. tuberculosis linked to resistance to first-
line and second-line antibiotics that can be used to
identify the mutations from a submitted sequence. This
database and its related software, MUBII, have been de-
veloped to satisfy the need of clinical microbiology labs
to easily analyze M. tuberculosis sequences and to link
the results to a potential therapeutic failure. MUBII
combines the use of reconstructed mutated gene se-
quences that can be searched by BLAST, aligned against
the wild-type gene sequence, and compared with the muta-
tion database. This concept can be easily adapted to the
microbiological identification of other microbial mutations.
Construction and contents
Mutations database
Data
The database was constructed based on a systematic re-
view of the literature, as described below. We focused
on publications reporting an association between specific
mutations in clinical isolates of M. tuberculosis and
phenotypic resistance to INH, RIF, PZA, FQs, and AMK.
The genes studied were rpoB for RIF; inhA, katG, and
the promoter region of the mabA(FabG1)-inhA operon
for INH; pncA for PZA; gyrA and gyrB for FQs; and rrs
for AMK. As a starting point, we used the TBDReaM
database because it constitutes a comprehensive resource
on drug resistance mutations in M. tuberculosis based on
studies published from January 1966 to December 2009
[23]. Additional publications on M. tuberculosis resistance
mutations recorded in MEDLINE from December 2009
to March 2013 were included in the analysis (see infra).
All publications reporting mutations, including the
ones recorded in the TBDReaM database, were care-
fully reviewed for the consistency of the information
about the mutated nucleotide and amino acid. We used
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the codon numbering given by the annotation of the
M. tuberculosis whole genome sequence published in [24].
Strategy of the systematic literature review
All studies reporting an association between specific muta-
tions in clinical isolates of M. tuberculosis and phenotypic
resistance to INH, RIF, PZA, FQs and AMK that were pre-
viously selected for the construction of the TBDReaM
database have been included again in our survey. More-
over, we searched the MEDLINE database for similar
works issued since the TBDReaM database release (Dec
2009 – Mar 2013). We also searched for additional refer-
ences in the bibliographies of the reports and reviews.
Only English language articles were considered. Combina-
tions of the following search terms were used:
Tuberculosis AND (mutation OR mutations) AND
(isoniazid OR rifampin OR fluoroquinolones OR ami-
kacin OR pyrazinamide OR katg OR maba OR fabg1
OR inha OR rpob OR rrs OR pnca OR gyra OR gyrb).
Inclusion criteria
A study was included in the database under the following
conditions: 1) it was a survey of clinical M. tuberculosis
isolates; 2) drug sensitivity testing was performed on all
isolates tested for mutations; and 3) the nucleotide or
codon position and the nucleotide or amino acid change
were given.
Data retrieval
We extracted and recorded information on the following:
1) the gene in which putative resistance mutations were
found and the nucleotide and/or codon position of the
mutation and 2) nucleotide and/or amino acid changes.
Studies that did not allow the extraction of the above data
or showed discrepancies in the wild-type sequences com-
pared with published M. tuberculosis genomes sequences
were excluded. The workflow of the literature review is
summarized in Figure 1. The extracted mutations and
original citations are supplied as Additional file 1.
Therapeutic relevance
Mutations with therapeutic relevance are tagged as
“high-confidence” mutations in the MUBII-TB-DB data-
base. High-confidence mutations have been previously de-
fined by Sandgren et al. [23] as mutations associated with
in vitro documented resistance reported by at least 10 pub-
lications based on the analysis of different sets of strains.
Reference sequences
The reference sequences of the resistance genes are
presented in Table 1.
Database grammar
For each gene, there is a corresponding separate subset
of the database, a text file with the description of a given
mutation on each line. The line contains both the de-
scriptions of the mutation (nucleotides and amino acids,
if applicable), notes on the mutation (for instance, thera-
peutic relevance) and rules to apply.
The database grammar (examples are presented in
Table 2) is as follows:
wildNPmutatedN ~ wildXPmutatedX[~Notes[~RULE::
type[,action][~Remarks]]]/~Remarks]
where P is the position on the nucleotide or protein
chain; N is a nucleotide (or short sequence); and X is
an amino-acid or a short peptide sequence. Notes are
written freely and may contain alphanumeric characters
and punctuation, except the tilde sign. The specific tag
“Rules::” identifies the actions to apply to clearly differ-
entiate the rules from the remarks. Rules modify the
computed result, for example, to suppress the peptide
sequence if a stop codon is created or to correct the re-
sult in the case of ambiguous positions of indels that
occur within repeated features. Remarks are not used by
the programs but are information, such as references
and dates, linked to the database entry.
Other data are also recorded in the database: the pos-
ition of the first codon of the nucleotide chain, the status
of the final main product (DNA/protein), and the DNA
sequence of the wild strain (the reference sequence).
Therefore, each gene-mutation database is a series of flat
files containing the descriptions of the mutations and
a series of files containing the character sequences in
FASTA format as well as the locations of the final gene
products and non-coding zones.
Implementation
MUBII is the analysis and interpretation engine and is
entirely written in Python 2.7. The external programs
that are called from Python are BLAST2seq [25], BLASTN,
BLASTX [26] and the alignment tools MUSCLE [27] and
MAFFT [28]. The routines transeq and showalign from
EMBOSS [29] are also used. The scheme of the global
organization is shown in Figure 2.
The Web interface exclusively uses CGI and HTML.
Cascading Style Sheets are used to color the alignments.
These decisions were made to achieve simplicity and
reliability on every browser. The Web server runs under
the APACHE MPM Prefork http server on a LINUX
Debian server.
De novo constructed BLASTN database
Only a few mutated sequences are available in GenBank;
therefore, the construction of a database containing the
sequences of all the described mutations is necessary. A
sequence database is built containing a unique mutation
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event for each of the sequences. It contains the descrip-
tions of the mutations present in MUBII-TB-DB, the ref-
erence sequence and the position of the promoter if
required. The mutated sequences are written in the
FASTA format at the nucleotide level with the descrip-
tion of the mutation as the descriptor. This database is re-
built when changes occur within MUBII-TB-DB and is
compiled as a BLAST database.
DNA sequence analysis
The query sequence for a given gene is submitted in the
FASTA format to the program through an HTML inter-
face. A preliminary nucleotide BLAST2seq against the
gene reference sequence is used to test if the query is
given as a + direct string and, if not, computes its com-
plementary strand. BLAST2seq does not allow for the
identification of mutations that may occur in the ex-
tremities of the sequence.
Alignment to the reference and extraction of the core of
the aligned sequences
The query sequence is aligned to the reference sequence
by MAFFT. An algorithm identifies the core of the
alignment by eliminating the trailing short sequences
that are not perfectly aligned at the extremities. The core
of the alignment is further used for mutation detection.
The alignment was initially produced using MUSCLE,
but as the program tries to align the whole length of the
reference sequence to a query that is often a partial se-
quence, the ends of the query were frequently assigned
to positions near the ends of the reference. This problem
was observed especially in the low quality-extremities of
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Figure 1 Study selection process and reasons for the exclusion of studies.
Table 1 List of the reference gene sequences of
Mycobacterium tuberculosis
Gene GenBank id.
rpoB [AL123456] REGION: 759808 to 763325
pncA (including the promoter) [AL123456] REGION: 2288681 to 2289280
promoter inhA [AL123456] REGION: 1673325 to 1673439
inhA [AL123456] REGION: 1674202 to 1675011
katG [AL123456] REGION: 2153889 to 2156111
identical to [×68081.1]
gyrA [AL123456] REGION: 7302 to 9818
gyrB [AL123456] REGION: 5123 to 7267
rrs [AL123456] REGION: 1471846 to 1473762
identical to [NR_102810]
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Table 2 Example of a mutation database: a part of the rpoB mutation database for Mycobacterium tuberculosis
Mutation description Explanation
A1291G ~ S431G ~ ~ Nucleotide chain: A at position 1291 is replaced by G; Protein chain: S at position 431
is replaced by G
+1300TTC ~ +434 F ~ ~ Insertion of TTC at position 1300 (F at position 434 of the protein)
CAG1306- ~ Q436- ~ ~ Deletion of CAG at position 1306 (deletion of Q at position 436 of the protein)
C1331T ~ T4441 ~ High Confidence ~ See mutDB2012 Example with a note and a remark
C1294T ~ Q432- ~ Rare ~ RULE::STOPCODON Example with a note and a rule
CATGGACCAGAA1299- ~ MDQN434- ~ ~RULE::AMBIGUOUS= >
N_ATGGACCAGAAC1300-
Example of a deletion occurring within a repeated zone. The position 1299 deduced
from the nucleotide-level sequence alignment is corrected in the results
Figure 2 MUBII general organization. The MUBII-TB-DB database and the de novo constructed mutation database (orange frame) are built before
the query session. The mutation database is used for the results interpretation and for the construction of the BLAST mutation database. Ovals indicate
the use of external software (dark green) or of MUBII routines (pale green). The query analysis process (green frame) combines the BLAST result
and the expertise of the alignment using the mutation database. Outputs are in blue.
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the query and has been found to occur less frequently
when using MAFFT.
Extraction of the mutations from the alignment and
identification
For the core section of the alignment, a program extracts
the non-matching sections and constructs a Python dic-
tionary of the results. Each entry of this dictionary is com-
pared with the entries of a mutation dictionary for the
given gene constructed from the MUBII-TB-DB database.
The resulting table contains a description of each point
mutation, insertion or deletion and indicates its presence
or absence in the database. In the case of deletion or inser-
tion, the possibility of frameshift creation is also checked,
and the result is added in an “alert” section. Moreover, if
the mutation is known and modifies the encoded protein,
this information is included. In the case of mutations usu-
ally identified by their positions in the Escherichia coli
gene (some sections of the rpoB gene), the E. coli gene
position is also computed. Finally, if the identified muta-
tion requires interpretation, the result is corrected to fulfill
the RULE:: indications. All results are saved in files in a
format ready for inclusion in the HTML page.
BLASTN on a reconstructed mutated sequence database
A BLASTN of the query against the constructed mu-
tated sequence database is performed, and the descrip-
tors of the best matching sequences are added to the
results. The whole BLASTN result is also saved.
DNA translation to protein
The protein translation of the core of the nucleotide
alignment is obtained using transeq from the EMBOSS
library.
Output page construction
An HTML output file is computed for the whole align-
ment (DNA and protein levels) that highlights mutations
using colored tags. The information gathered in the
various results files is returned (detected mutations and
frameshifts, mutation identification, BLAST result on
the reconstructed sequence database, position within the
M. tuberculosis wild-type gene, and, if possible, position
within the E. coli gene). The results, alerts and alignment
are placed in iframes that enable horizontal browsing
and searching to inspect sequences for mutations. A
specific output adapted for printing is constructed. It
provides information about the detected mutations along
with alignments using the showalign EMBOSS routine.
Quality control
We have used the in silico mutation generation routine
of MUBII to generate a mutated version of the M. tuber-
culosis H37Rv sequence. For every gene and every
mutation described in MUBII-TB-DB, we have con-
structed a sequence containing the required modifica-
tion (e.g., base change, deletion, insertion). The mutated
sequence thus obtained was then submitted to MUBII to
verify the accuracy of the answer. All described muta-
tions as well as hundreds of random mutations have
been checked, and the MUBII results have been carefully
analyzed. This procedure has identified uncertainties in
mutation identification when an indel occurs near or
within repeated features, especially in the rpoB gene. An
interpretation RULE has been added to indicate such a
situation and modify the answer accordingly. Following
this extended quality control, both the MUBII-TB-DB
database and the MUBII process have been validated
for use.
Utility and discussion
Data input
The use of MUBII is straightforward, as the submission
of the FASTA formatted sequence and the name of the
corresponding gene are performed using a standard
Web browser. It is also possible to use a test sequence
for demonstration purposes or to verify the system.
Data analysis
The result appears in a new html page embedding the
presentation of the DNA and protein alignments along
with the sequence of the wild-type strain. The first
section of the result pages concerns the nucleotide se-
quence (Figure 3). This section shows the DNA align-
ment of the query against the wild-type sequence and
highlights any mutations. When mutations are detected,
alerts are printed to note the position and the type of
the mutation, its status (already described or unknown,
therapeutic relevance), and situations such as frame-
shifts. At the end of this section, the name of the best
matching sequence in the BLAST of the query against
the reconstructed database of mutated sequences is shown.
Access to the whole BLAST result is also possible. Because
only a few strains of M. tuberculosis carry double mu-
tations, the database contains only singly mutated se-
quences. The second section concerns the protein
corresponding to the core nucleotide sequence. This
section shows the peptide-level alignment of the query
against the wild-type sequence and the position of
mutations. The alignment is deduced from the nucleo-
tide alignment and highlights the mutations and ob-
served changes in the case of frameshift. In this last
case, as the gaps are not introduced, the picture shows
the actual changes observed in the query. This presen-
tation is more informative, for the biologist, of the real
changes that occur (Figure 4). When a stop-codon
mutation is created, a specific alert is highlighted, and
the shortened version of the protein is shown.
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Utility and discussion
The MUBII algorithm and the MUBII-TB-DB resistance
database have been tested using amplified sequences from
MTBC strains isolated in our laboratory since January
2010 (approximately 350 strains, including 30 TB-MDR
strains from our collection). No mutation was detected in
the MTBC strains that were classified as susceptible to
the antibiotics using the in vitro susceptibility test. The
mutations detected in the TB-MDR strains were fully
concordant with the mutations identified in the French
National Reference Centre for Mycobacteriology (National
Microbiology Laboratory, Hôpital de la Pitié-Salpétrière,
Paris, France). MUBII-TB-DB has been used routinely
by 12 molecular biology laboratory technicians and 6
microbiologists in the Mycobacteria laboratory of the Uni-
versity hospital in Lyon, France for eight months. The la-
boratory technicians were trained to work with websites
and a laboratory information management system. A very
short demonstration of the use of the website was pro-
vided to each laboratory technician through the analysis
of real samples. The website has been unanimously judged
as user-friendly, especially because of the direct indication
of mutations and the printed results that are included
in the patient's record. The microbiologists who tested
MUBII-TB-DB preferred its output over the previous
time-consuming method combining blast2seq (at the
DNA and protein levels) with searches in a local database
(both electronic and paper) and/or TBDReaM database.
Figure 3 Screen capture of an rpoB query: DNA alignment and detected mutations. The figure shows an example of the detection of a
mutation. The whole nucleotide alignment can be observed by horizontally scrolling the alignment window. In the case of the rpoB gene
mutation, the nucleotide positions in M. tuberculosis and E. coli are indicated. The protein scheme compares the wild-type and query sequences
for a given position. This scheme describes the changes along the protein sequence and emphasizes the effect of the mutation on
the protein chain.
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Conclusions
The growing incidence and spread of antibiotic-resistant
M. tuberculosis has led to efforts to identify the muta-
tions in clinical isolates. The mutations linked to therapy
failure are a particularly serious concern for physicians
managing TB patients. The reference method is to se-
quence the gene of interest and then to detect and iden-
tify possible mutations. This process is time consuming,
as there is no mutation database directly coupled to an
analysis tool that allows for the submission of a se-
quence, its comparison to the database and the immedi-
ate analysis of the results. MUBII-TB-DB is a structured
database collecting the description and information on
modifications to seven loci of major therapeutic value in
tuberculosis. The simple structure and grammar of
MUBII-TB-DB contribute to the evolving capacity of the
database, which can be easily updated with new entries
(both mutations and resistance genes). MUBII-TB-DB is
adapted to MUBII, a query and interpretation engine
that is interrogated via a website. The sequence of a gene
implicated in TB antibiotic resistance is analyzed simul-
taneously as a DNA string by BLAST against a de novo
constructed sequence database and by an alignment
process for the DNA and protein sequences. The results
are graphs (alignments) and text (description of the mu-
tation, previous description, therapeutic signification).
MUBII-TB-DB is fast and easy to use, even by technicians
without bioinformatics training. The system provides ac-
cess to an interpretation in biological and therapeutic
terms. It enables the automation of repetitive and some-
what technically challenging tasks in the tuberculosis la-
boratory. Its interest is to provide easy and comprehensive
access to an up-to-date antibiotic resistance database
concerning M. tuberculosis. Moreover, our algorithm is
applicable to any mutation database and to any micro-
organism, making MUBII a useful tool for the surveillance
and control of multidrug-resistant microorganisms.
Availability
The database is available at http://umr5558-bibiserv.univ-
lyon1.fr/mubii/mubii-select.cgi.
Additional file
Additional file 1: Mutation database references spreadsheet.
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